Technical Analysis for IMNN - Imunon, Inc.

Grade Last Price % Change Price Change
F 0.78 -6.44% -0.05
IMNN closed down 6.44 percent on Tuesday, November 12, 2024, on 2.12 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Earnings Movers Other 0.00%
Outside Day Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -6.44%
Lizard Bullish Bullish Day Trade Setup -6.44%
Calm After Storm Range Contraction -6.44%

   Recent Intraday Alerts

Alert Time
Up 1% about 11 hours ago
Lower Bollinger Band Support about 11 hours ago
Possible NR7 about 11 hours ago
Lizard Bullish Entry about 14 hours ago
Hammer Candlestick Entry about 14 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Imunon, Inc. Description

Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Immunotherapy Infectious Diseases Tumor Virotherapy Immunotherapies Human Diseases Virus Platform Technologies Biomolecules Two Platform Technologies

Is IMNN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.65
52 Week Low 0.48
Average Volume 213,710
200-Day Moving Average 1.13
50-Day Moving Average 1.00
20-Day Moving Average 0.93
10-Day Moving Average 0.90
Average True Range 0.07
RSI (14) 29.58
ADX 16.31
+DI 12.10
-DI 26.39
Chandelier Exit (Long, 3 ATRs) 0.88
Chandelier Exit (Short, 3 ATRs) 0.97
Upper Bollinger Bands 1.06
Lower Bollinger Band 0.80
Percent B (%b) -0.09
BandWidth 28.44
MACD Line -0.05
MACD Signal Line -0.04
MACD Histogram -0.0149
Fundamentals Value
Market Cap 7.29 Million
Num Shares 9.4 Million
EPS -3.25
Price-to-Earnings (P/E) Ratio -0.24
Price-to-Sales 38.91
Price-to-Book 0.27
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.89
Resistance 3 (R3) 0.90 0.87 0.87
Resistance 2 (R2) 0.87 0.84 0.87 0.87
Resistance 1 (R1) 0.82 0.82 0.81 0.81 0.86
Pivot Point 0.79 0.79 0.78 0.79 0.79
Support 1 (S1) 0.74 0.76 0.73 0.74 0.69
Support 2 (S2) 0.71 0.74 0.71 0.68
Support 3 (S3) 0.67 0.71 0.68
Support 4 (S4) 0.66